SCHEMBL256708

SCHEMBL256708

CC/C=C/c1ccc(OC)cc1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.59
CYP3A4 P08684 2/20 0.59
LMNA P02545 2/20 0.59
TP53 P04637 1/20 0.59
TSHR P16473 1/20 0.59
ALDH1A1 P00352 1/20 0.59
TRPA1 O75762 1/20 0.57
RELA Q04206 1/20 0.57
ESR1 P03372 3/20 0.55
CYP1A2 P05177 3/20 0.55
CYP1A1 P04798 3/20 0.55
CYP1B1 Q16678 3/20 0.55
AHR P35869 3/20 0.55
PTGS2 P35354 2/20 0.55
ABL1 P00519 1/20 0.55
TTR P02766 1/20 0.55
ABCB1 P08183 1/20 0.55
ALOX5 P09917 1/20 0.55
BCR P11274 1/20 0.55
CYP19A1 P11511 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12047534 1.00 KDM4E (0.59) KDM4ECYP3A4LMNATP53TSHR
SCHEMBL8647769 1.00 KDM4E (0.59) KDM4ECYP3A4LMNATP53TSHR
SCHEMBL13778032 0.94 KDM4E (0.53) KDM4ECYP3A4LMNATP53TSHR
SCHEMBL9954760 0.90 NFE2L2 (0.55) KDM4ECYP3A4LMNATP53TSHR
SCHEMBL9954764 0.90 NFE2L2 (0.55) KDM4ECYP3A4LMNATP53TSHR
SCHEMBL9954765 0.90 NFE2L2 (0.55) KDM4ECYP3A4LMNATP53TSHR
SCHEMBL9960769 0.90 NFE2L2 (0.55) KDM4ECYP3A4LMNATP53TSHR
SCHEMBL22252716 0.86 KDM4E (0.53) KDM4ECYP3A4LMNATP53TSHR
SCHEMBL31336548 0.85 KDM4E (0.48) KDM4ECYP3A4LMNATP53TSHR
SCHEMBL31336333 0.85 KDM4E (0.48) KDM4ECYP3A4LMNATP53TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11739074-B2 Ras inhibitors Revolution Medicines, Inc. (US) 2023-08-29 US disclosed
US-20230233569-A1 METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT 2023-07-27 US disclosed
CN-112266352-B Piperlongumine derivative and preparation method and application thereof 绍兴文理学院 2022-02-08 CN disclosed
US-20210179648-A1 P2X3 AND/OR P2X2/3 RECEPTOR ANTAGONIST, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USE THEREOF BEIJING TIDE PHARMACEUTICAL CO., LTD. (CN) 2021-06-17 US disclosed
US-10934531-B2 Method for enantioselective carbene C—H insertion using an iron-containing protein catalyst CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 2021-03-02 US disclosed
US-10934531-B2 Method for enantioselective carbene C—H insertion using an iron-containing protein catalyst CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 2021-03-02 US disclosed
CN-108383694-B Preparation method of cyclobutane derivative 华中科技大学 2020-09-18 CN disclosed
CN-110878001-A Process for the isomerization of (Z) -olefins to (E) -olefins 温州大学 2020-03-13 CN disclosed
US-20190276805-A1 METHOD FOR ENANTIOSELECTIVE CARBENE C-H INSERTION USING AN IRON-CONTAINING PROTEIN CATALYST CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 2019-09-12 US disclosed
US-20190276805-A1 METHOD FOR ENANTIOSELECTIVE CARBENE C-H INSERTION USING AN IRON-CONTAINING PROTEIN CATALYST CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 2019-09-12 US disclosed
US-20120009615-A1 DIPYRROMETHENE-BORON HYDROPHILIC FLUORESCENT COMPOUNDS UNIVERSITE DE STRASBOURG (50% PART INTEREST) (FR) 2012-01-12 US disclosed
US-20110281862-A1 ALFA-CARBOLINE INHIBITORS OF NPM-ALK, RET, AND BCR-ABL UNIVERSITA' DEGLI STUDI DI MILANO - BICOCCA (IT) 2011-11-17 US disclosed
EP-2055746-A2 Colored curable composition, color filter, method of producing the same, and solid state image pickup device. Fujifilm Corporation (JP) 2009-05-06 EP disclosed
US-20070244160-A1 6-11 Bicyclic Ketolide Derivatives OR YAT SUN 2007-10-18 US disclosed
US-7169786-B2 Isoxazoline derivatives as anti-depressants JANSSEN-CILAG S.A. (ES) 2007-01-30 US disclosed
US-7169786-B2 Isoxazoline derivatives as anti-depressants JANSSEN-CILAG S.A. (ES) 2007-01-30 US disclosed
US-5466838-A Catalytic reaction of olefin with oxygen in the presence of aldehyde SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1995-11-14 US disclosed
EP-0540009-B1 Process for producing epoxides SUMITOMO CHEMICAL CO (JP) 1995-08-30 EP disclosed
US-5367087-A Process for producing epoxide SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1994-11-22 US disclosed
EP-0540009-A1 Process for producing epoxides SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1993-05-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210179648-A1 P2X3 AND/OR P2X2/3 RECEPTOR ANTAGONIST, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USE THEREOF P2RX3, P2RX2, P2RX7 KDM4E 4725/4885CYP3A4 2252/4885LMNA 1680/4885
US-11739074-B2 Ras inhibitors KRAS, NRAS, HRAS KDM4E 3344/4885CYP3A4 3310/4885LMNA 3858/4885
US-20070244160-A1 6-11 Bicyclic Ketolide Derivatives AKR1C2, AKR1C3, AKR1C1 KDM4E 56/4885CYP3A4 24/4885LMNA 4270/4885
US-20110281862-A1 ALFA-CARBOLINE INHIBITORS OF NPM-ALK, RET, AND BCR-ABL ALK, BCR, NPM1 KDM4E 2789/4885CYP3A4 3175/4885LMNA 1863/4885
US-20120009615-A1 DIPYRROMETHENE-BORON HYDROPHILIC FLUORESCENT COMPOUNDS LDHB, AHR, BCR KDM4E 4804/4885CYP3A4 2316/4885LMNA 94/4885
US-20230233569-A1 METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS KRAS, HRAS, MTOR KDM4E 2157/4885CYP3A4 4873/4885LMNA 1680/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.